These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31826177)

  • 1. Prevalence of ERG expression and PTEN loss in a Brazilian prostate cancer cohort.
    Morais CE; Gurgel DC; Teixeira AC; Mattos TVA; Silva AVAD; Tavora F
    Braz J Med Biol Res; 2019; 52(12):e8483. PubMed ID: 31826177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
    Tosoian JJ; Almutairi F; Morais CL; Glavaris S; Hicks J; Sundi D; Humphreys E; Han M; De Marzo AM; Ross AE; Tomlins SA; Schaeffer EM; Trock BJ; Lotan TL
    Eur Urol; 2017 May; 71(5):697-700. PubMed ID: 27477529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
    Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
    PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN Loss but Not ERG Expression in Diagnostic Biopsies Is Associated with Increased Risk of Progression and Adverse Surgical Findings in Men with Prostate Cancer on Active Surveillance.
    Lokman U; Erickson AM; Vasarainen H; Rannikko AS; Mirtti T
    Eur Urol Focus; 2018 Dec; 4(6):867-873. PubMed ID: 28753869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
    Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
    Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
    Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
    Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
    Huang KC; Evans A; Donnelly B; Bismar TA
    Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling.
    Shah RB; Bentley J; Jeffery Z; DeMarzo AM
    Hum Pathol; 2015 May; 46(5):698-706. PubMed ID: 25724568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
    Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
    Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
    Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
    Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas.
    Downes MR; Satturwar S; Trudel D; van der Kwast TH
    Pathol Res Pract; 2017 Jan; 213(1):34-38. PubMed ID: 27913052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
    Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
    Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Hernández-Llodrà S; Segalés L; Juanpere N; Marta Lorenzo T; Salido M; Nonell L; David López T; Rodríguez-Vida A; Bellmunt J; Fumadó L; Cecchini L; Lloreta-Trull J
    Prostate; 2021 Dec; 81(16):1267-1277. PubMed ID: 34533858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
    BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.